Price (delayed)
$1.35
Market cap
$6.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.46
Enterprise value
-$18.66M
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live
There are no recent dividends present for ADXS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.